Trial Profile
A Randomized, Double-blind Phase I Trial to Evaluate the Safety, Tolerability, and Immunogenicity of DCB07010 Adjuvant Given Intranasally at Ascending Dose Levels and Co-administered With Trivalent Inactivated Influenza Virus Antigen
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Advagene Biopharma
- 02 Mar 2019 Results assessing the safety and immunogenicity of the intranasally administered trivalent influenza vaccine adjuvanted with LTh(aK)published in the Vaccine
- 05 Oct 2017 New trial record